This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Exelixis's Cabometyx Positive for First-Line Kidney Cancer
by Zacks Equity Research
Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.
J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study
by Zacks Equity Research
Johnson & Johnson (JNJ) announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica against Pfizer's Torisel for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).
The Zacks Analyst Blog Highlights: Chevron, Pfizer, Boeing, 3M and Citigroup
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, Pfizer, Boeing, 3M and Citigroup
3 Biotech Stocks That More than Doubled Year to Date
by Arpita Dutt
Here is a look at Puma (PBYI) and two other biotech stocks that have recorded massive gains so far in 2017.
Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused
by Arpita Dutt
Merck (MRK) paused patient enrolment in a couple of studies being conducted with its anti-PD-1 therapy, Keytruda.
Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug
by Zacks Equity Research
Pfizer, Inc. (PFE) announced a deal to buy exclusive EU commercialization rights to an anti-fungal treatment, Cresemba from Swiss pharma company, Basilea Pharmaceutica Ltd.
Acceleron (XLRN) Kidney Cancer Candidate Fails in Phase II
by Zacks Equity Research
Acceleron Pharma Inc.'s (XLRN) announced disappointing results from a phase II study evaluating its pipeline candidate dalantercept in combination with Pfizer's (PFE) Inlyta (axitinib) for treatment of advanced renal cell carcinoma (RCC).
Pfizer & Lilly Get Fast Track Designation for Pain Candidate
by Zacks Equity Research
Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) announced that the FDA has granted fast track designation to their pipeline candidate, tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP).
Company News for June 14, 2017
by Zacks Equity Research
Companies in the News are: LLY,PFE,CAKE,JW.A,CVCO
Merck's Diabetes Drug Meets Primary Endpoint in Key Studies
by Zacks Equity Research
Merck & Co., Inc. (MRK) and partner Pfizer Inc. (PFE) announced that its pipeline candidate, ertugliflozin, met primary endpoints in two late stage studies evaluating ertugliflozin in adults with Type 2 diabetes.
AbbVie (ABBV) Announced Positive Phase III RA Candidate Data
by Zacks Equity Research
AbbVie Inc. (ABBV) announced positive top-line results from a phase III study on rheumatoid arthritis candidate, upadacitinib (ABT-494).
Pfizer's (PFE) Tafamidis Gets Fast Track Status in the U.S.
by Zacks Equity Research
Pfizer Inc. (PFE) has been granted with fast track status by FDA for treating patients with transthyretin cardiomyopathy (TTR-CM).
Roche Announces Data on Perjeta, Alecensa and Tecentriq
by Zacks Equity Research
Roche announced a series of data on various cancer drugs like Perjeta, Alecensa and Tecentriq at ASCO.
Merck's Cancer Drug Keytruda Positive in Clinical Studies
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced positive data from a phase III study KEYNOTE-024, evaluating its anti-PD-1 therapy, Keytruda (pembrolizumab) for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC).
Pfizer Provides Final Update on Phase II Talazoparib Study
by Zacks Equity Research
Pfizer Inc. (PFE) announced data from its phase II study, ABRAZO, which is evaluating talazoparib in advanced breast cancer patients with germline BRCA 1/2 positive (gBRCA+) mutations, showing anti-tumor activity
Pfizer (PFE) Down 2.5% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pfizer's Kidney Cancer Drug Gets Acceptance in the U.S. & EU
by Zacks Equity Research
Pfizer Inc. (PFE) announced encouraging news with the FDA and the European Medicines Agency (EMA) accepting the company's regulatory submission for label expansion of its cancer drug, Sutent (sunitinib).
Pharma Stock Roundup: Positive Data from Lilly & Teva, BMY's Deals & More
by Arpita Dutt
Lilly (LLY) posted positive data on Cyramza while Teva's migraine drug delivered positive results in a late-stage study.
Pfizer's Trumenba Vaccine Approved by European Commission
by Zacks Equity Research
Pfizer Inc. (PFE) announced that its Trumenba vaccine received approval from the European Commission (EC) for active immunization of people aged 10 years and older for the prevention of invasive disease caused by Neisseria meningitidis serogroup B (MenB).
Pfizer's Epogen Biosimilar Gets Positive FDA Committee Vote
by Zacks Equity Research
Pfizer, Inc. (PFE) announced that an FDA advisory committee has recommended approval of its biosimilar version of ESA Epogen and Procrit.
Celldex's Immuno-Oncology Pipeline Continues to Impress
by Zacks Equity Research
On May 25, we issued an updated research report on Hampton, NJ-based Celldex Therapeutics, Inc. (CLDX).
Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data
by Arpita Dutt
Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.
Aerie's Ophthalmic Candidate Positive in Registration Trial
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) announced positive primary efficacy results of the 90-day phase III registration trial -- Mercury 2 -- for its pipeline candidate Roclatan.
Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara.
Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug
by Zacks Equity Research
Shire plc (SHPG) announced positive top-line results from the phase III study, HELP, on HAE candidate, lanadelumab.